Neues bei Kopfschmerzen

Zusammenfassung

Die folgende Übersicht soll darstellen, was sich in der Epidemiologie, Pathophysiologie, Akuttherapie und Prophylaxe verschiedener Kopfschmerzarten in der zweiten Jahreshälfte 1999 und im Jahr 2000 Neues getan hat.

New Publications on Headache

This review summarizes new publications dealing with the epidemiology, pathophysiology, acute therapy and prevention of headache which appeared in the second half of 1999 and in 2000.

Literatur

• 1 Rasmussen B K. Epidemiology of headache.  Cephalalgia. 1995;  15 44-45
• 2 Launer L J, Terwindt G M, Ferrari M D. The prevalence and characteristics of migraine in a population-based cohort. The GEM-study.  Neurology. 1999;  53 537-542
• 3 Marcus D A, Scharff L, Turk D. Longitudinal prospective study of headache during pregnancy and postpartum.  Headache. 1999;  39 625-632
• 4 Ulrich V, Gervil M, Kyvik K O. et al . Evidence of a genetic factor in migraine with aura: a population-based danish twin study.  Ann Neurol. 1999;  45 242-246
• 5 Gervil M, Ulrich V, Kyvik K. et al . Migraine without aura: a population-based twin study.  Ann Neurol. 1999;  46 606-611
• 6 Roon K I, Olesen J, Diener H C. et al . No acute antimigraine efficiacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials.  Ann Neurol. 2000;  47 238-241
• 7 May A, Shepheard S L, Knorr M. et al . Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine.  Brain. 1998;  121 1231-1237
• 8 May A, Gijsman H J, Wallnöfer A. et al . Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks.  Pain. 1996;  67 375-378
• 9 Cutler N R, Gomez-Mancilla B, Leibowitz M T, Fleishaker J. A study of safety and efficacy in patients with acute migraine, using PNU-142633, a selective 5-HT_1D agonist (abstract).  Cephalalgia. 2000;  20 268
• 10 Burstein R, Yarnitsky D, Goor-Aryeh I. et al . An association between migraine and cutaneous allodynia.  Ann Neurol. 2000;  47 614-624
• 11 Gallagher R M, Dennish G, Spierings E LH, Chitra R. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine.  Headache. 2000;  40 119-128
• 12 Überall M A, Wenzel D. Intranasal sumatriptan for the acute treatment of migraine in children.  Neurology. 1999;  52 1507-1510
• 13 Krymchantowski A V, Adriano M, Fernandes D. Tolfenamic acid decreases migraine recurrence when used with sumatriptan.  Cephalalgia. 1999;  19 186-187
• 14 Tfelt-Hansen P, Saxena P R, Dahlöf C. et al . Ergotamine in the acute treatment of migraine. A review and European consensus.  Brain. 2000;  123 9-18
• 15 Diener H. for the ASASUMAMIG Study Group . Efficacy and safety of intravenous acetylsalicyclic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study.  Cephalalgia. 1999;  19 581-588
• 16 Bates D, Ashford E, Dawson R. et al . Subcutaneous sumatriptan during the migraine aura.  Neurology. 1994;  44 1587-1592
• 17 Kaube H, Herzog J, Käufer T. et al . Ketamine can stop aura in hemiplegic migraine (abstract).  Cephalalgia. 2000;  20 270
• 18 Bussone G, Gerbo R, Martucci N. et al . Alpha-dihydroergocryptine in the prophylaxis of migraine: a multicenter double-blind study versus fIunarizine.  Headache. 1999;  39 426-431
• 19 Arnold G, Einhäupl K M. Valproinsäure in der prophylaktischen Behandlung der Migräne.  Nervenarzt. 1998;  69 913-918
• 20 Diener H C, Gendolla A, Limmroth V. Valproinsäure in der Migräneprophylaxe.  Akt Neurol. 1996;  23 265-268
• 21 Steiner T J, Findley L J, Yuen A WC. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura.  Cephalalgia. 1997;  17 109-112
• 22 Melchart D, Linde K, Fischer P. et al . Acupuncture for recurrent headaches: a systematic review of randomized controlled trials.  Cephalalgia. 1999;  19 779-786
• 23  The International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. First edition.  Cephalalgia. 1991;  11 1-12
• 24 Carruthers A, Langtry J AA, Carruthers J, Robinson G. lmprovement of tension-type headache when treating wrinkles with botulinum toxin A injections.  Headache. 1999;  39 662-665
• 25 Smuts J A, Baker M K, Smuts H M. et al . Prophylactic treatment of chronic tension-type headache using botulinum toxin type A.  Eur J Neurol. 1999;  6, Suppl 4 S99-S102
• 26 Silberstein S D, Niknam R, Rozen T D, Young W B. Cluster headache with aura.  Neurology. 2000;  54 219-221
• 27 Wheeler S D, Carrazana E J. Topiramate-treated cluster headache.  Neurology. 1999;  53 234-236
• 28 Bahra A, Walsh M, Menon S, Goadsby P J. Does chronic daily headache arise de novo in association with regular analgesic use? (abstract).  Cephalalgia. 2000;  20 294
• 29 Kaube H, May A, Diener H G, Pfaffenrath V. Sumatriptan misuse in daily chronic headache.  BMJ. 1994;  308 1573
• 30 Limmroth V, Kazarawa S, Fritsche G, Diener H G. Headache after frequent use of new 5-HT agonists zolmitriptan and naratriptan.  Lancet. 1999;  353 378
• 31 Katsarava Z, Fritsche G, Diener H G, Limmroth V. Drug-induced headache (DIH) following the use of different triptans.  Cephalalgia. 2000;  20 293
• 32 Connelly N R, Parker R K, Rahimi A, Gibson C S. Sumatriptan in patients in postdural puncture headache.  Headache. 2000;  40 316-319